🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesMy dad had a heart attack and now I am terrified - will GLP-1 help?

My dad had a heart attack and now I am terrified - will GLP-1 help?

FitDadDave Sun, May 3, 2026 at 7:22 AM 5 replies 485 viewsPage 1 of 1
FitDadDave
Member
534
2,678
Jul 2024
Minneapolis, MN
May 3, 2026 at 7:22 AM#1

My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

What would genuinely help is knowing how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

I would rather have one careful answer than five confident ones.

32 2Dr.NephBHM_UK, kim_atl_prep, sarah_TO and 29 others
Reply Quote Save Share Report
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
May 3, 2026 at 7:48 AM#2
FitDadDave said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].

Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.

References:
[1] Marso SP, et al. N Engl J Med. 2016;375(19):1834-1844.
31 1laura_annarbor, JenMemphis, pat_auckland and 28 others
Reply Quote Save Share Report
KevinCompounds
VIP Member
5,432
18,234
Dec 2023
Nevada
May 3, 2026 at 8:14 AM#3
LabKate said:
SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk.
LabKate said:
...we don't know the long-term effects of cardiovascular risk...

This is a fair point, and I think intellectual honesty requires acknowledging it. GLP-1 agonists in their current form have ~8-10 years of human exposure data. That's not nothing, but it's not 30+ years either.

However: the risk-benefit calculation should also consider the KNOWN long-term effects of untreated obesity — diabetes, cardiovascular disease, cancer, joint destruction, reduced lifespan by 5-10 years.

Uncertainty about GLP-1 long-term safety vs certainty about obesity consequences. The calculus seems clear to me, but reasonable people can disagree.

30 0MikeKY_noInsulin, Dr.RaviCardio, jennifer_SEA and 27 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
maria_elpaso
Member
312
1,456
Sep 2024
El Paso, TX
May 3, 2026 at 8:40 AM#4
FitDadDave said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Can confirm. Same sequence, different timescale.

29 24HPLC_Greg, LibrarianMeg, bri_stats and 26 others
Reply Quote Save Share Report
sophie_paris
Member
212
890
Nov 2024
Paris, FR
May 3, 2026 at 11:00 AM#5

Adding the clinical framing, because it changes how the question reads.

Senior perspective on cardiovascular risk: I'm 68 years old and started this journey skeptically. My internist recommended it after years of failed interventions.

8 months later: down 41 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

Last edited: May 3, 2026 at 4:00 PM
28 23BethLabQueen, ChrisMacros, KetoKyle and 25 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register